We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Blackbaud, Inc. (BLKB - Free Report) delivered third-quarter 2019 non-GAAP earnings of 56 cents per share, outpacing the Zacks Consensus Estimate of 50 cents. However, the figure declined 5.1% from the year-ago quarter.
Total non-GAAP revenues improved 5.4% year over year to $221.4 million, surpassing the Zacks Consensus Estimate of $220 million.
Blackbaud’s stock has gained 37.3% on a year-to-date basis, outperforming the industry's rally of 31.3%.
Quarter in Detail
Blackbaud reports maintenance and subscriptions under recurring revenues as it is shifting toward a cloud-based subscription model from the traditional revenue-based model.
Total non-GAAP recurring revenues for the reported quarter were $205.5 million, accounting for 92.8% of total non-GAAP revenues. The figure was also up 8.6% year over year.
One-time services and other revenues were $15.9 million, declining 23.9% year over year.
Non-GAAP organic revenues improved 2.7% year over year to $215.9 million. Meanwhile, non-GAAP organic recurring revenues advanced 5.6% to $199.7 million.
Margin Details
Non-GAAP gross margin contracted 100 bps to 59.5%.
Non-GAAP operating margin contracted 240 bps from the year-ago figure to 16.5%. The decrease can primarily be attributed to higher investments.
Balance Sheet & Cash Flow
As on Sep 30, 2019, Blackbaud had cash and cash equivalents of $29.1 million compared with $32.7 million at the end of the previous quarter. Total debt (including current portion) amounted to $503.1 million compared with $561.3 million reported at the end of the last reported quarter.
Cash flow from operating activities during the nine months ended Sep 30, 2019, was $122.1 million. Free cash flow during the quarter was $62.5 million.
The company recently approved a quarterly dividend payment of 12 cents per share to be paid out on Dec 13, 2019, to shareholders as of Nov 27, 2019.
Guidance
Blackbaud maintained 2019 outlook. The company anticipates revenues of $880-$910 million (mid-point $895 million) for 2019. The Zacks Consensus Estimate is currently pegged at $893.9 million.
It anticipates non-GAAP earnings per share of $2.11-$2.28 per share (mid-point of $2.20) for 2019. The Zacks Consensus Estimate is pegged at $2.22 per share.
Non-GAAP operating margin is projected to be 16.7-17.2%.
Blackbaud continues to anticipate non-GAAP free cash flow of $124-$134 million for 2019.
Zacks Rank & Stocks to Consider
Currently, Blackbaud carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader technology sector are Vonage Holdings Corp. , Hewlett Packard Enterprise Company (HPE - Free Report) and Taiwan Semiconductor Manufacturing Company Ltd. (TSM - Free Report) . Each of the stocks flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Long-term earnings growth rates for Vonage, Hewlett Packard Enterprise and Taiwan Semiconductor are currently pegged at 5%, 7.1% and 10.4%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Blackbaud (BLKB) Q3 Earnings & Revenues Surpass Estimates
Blackbaud, Inc. (BLKB - Free Report) delivered third-quarter 2019 non-GAAP earnings of 56 cents per share, outpacing the Zacks Consensus Estimate of 50 cents. However, the figure declined 5.1% from the year-ago quarter.
Total non-GAAP revenues improved 5.4% year over year to $221.4 million, surpassing the Zacks Consensus Estimate of $220 million.
Blackbaud’s stock has gained 37.3% on a year-to-date basis, outperforming the industry's rally of 31.3%.
Quarter in Detail
Blackbaud reports maintenance and subscriptions under recurring revenues as it is shifting toward a cloud-based subscription model from the traditional revenue-based model.
Total non-GAAP recurring revenues for the reported quarter were $205.5 million, accounting for 92.8% of total non-GAAP revenues. The figure was also up 8.6% year over year.
One-time services and other revenues were $15.9 million, declining 23.9% year over year.
Non-GAAP organic revenues improved 2.7% year over year to $215.9 million. Meanwhile, non-GAAP organic recurring revenues advanced 5.6% to $199.7 million.
Margin Details
Non-GAAP gross margin contracted 100 bps to 59.5%.
Non-GAAP operating margin contracted 240 bps from the year-ago figure to 16.5%. The decrease can primarily be attributed to higher investments.
Balance Sheet & Cash Flow
As on Sep 30, 2019, Blackbaud had cash and cash equivalents of $29.1 million compared with $32.7 million at the end of the previous quarter. Total debt (including current portion) amounted to $503.1 million compared with $561.3 million reported at the end of the last reported quarter.
Cash flow from operating activities during the nine months ended Sep 30, 2019, was $122.1 million. Free cash flow during the quarter was $62.5 million.
The company recently approved a quarterly dividend payment of 12 cents per share to be paid out on Dec 13, 2019, to shareholders as of Nov 27, 2019.
Guidance
Blackbaud maintained 2019 outlook. The company anticipates revenues of $880-$910 million (mid-point $895 million) for 2019. The Zacks Consensus Estimate is currently pegged at $893.9 million.
It anticipates non-GAAP earnings per share of $2.11-$2.28 per share (mid-point of $2.20) for 2019. The Zacks Consensus Estimate is pegged at $2.22 per share.
Non-GAAP operating margin is projected to be 16.7-17.2%.
Blackbaud continues to anticipate non-GAAP free cash flow of $124-$134 million for 2019.
Zacks Rank & Stocks to Consider
Currently, Blackbaud carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader technology sector are Vonage Holdings Corp. , Hewlett Packard Enterprise Company (HPE - Free Report) and Taiwan Semiconductor Manufacturing Company Ltd. (TSM - Free Report) . Each of the stocks flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Long-term earnings growth rates for Vonage, Hewlett Packard Enterprise and Taiwan Semiconductor are currently pegged at 5%, 7.1% and 10.4%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>